Download full text PDF

A.V. Kovalenko Student, Department of Biotechnology and Industrial Pharmacy, MIREA – Russian University of Technology (Moscow) D.O. Shatalov Ph.D. (Pharm.), Associate Professor, Department of Biotechnology and Industrial Pharmacy, MIREA – Russian University of Technology; Deputy Executive Director, Institute of Pharmaceutical Technologies JSC (Moscow) E-mail: S.A. Kedik Dr.Sc. (Tech.), Professor, Head of the Department of Biotechnology and Industrial Pharmacy, MIREA – Russian University of Technology; Executive Director, Institute of Pharmaceutical Technologies JSC (Moscow) A.I. Gromakova Dr.Sc. (Pharm.), Chief Researcher of the Scientific and Organizational Department, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) A.P. Kaplun Dr.Sc. (Chem.), Рrofessor, Department of Biotechnology and Industrial Pharmacy, MIREA – Russian University of Technology (Moscow) I.S. Ivanov Post-graduate Student, Department of Biotechnology and Industrial Pharmacy, MIREA – Russian University of Technology (Moscow) I.V. Sterin Student, Department of Biotechnology and Industrial Pharmacy, MIREA – Russian University of Technology (Moscow)

Eye pathologies are serious diseases of modern man. Conjunctivitis make up about 35% of all eye diseases, they are the main clinical forms of eye infection – 66.7% of the total number of patients with inflammatory eye diseases. Conjunctivitis is an inflammatory disease of the conjunctiva, a thin transparent tissue that lines the inner surface of the eyelid and the visible part of the sclera, which has an infectious or other etiology. Infectious conjunctivitis is classified according to the course of the disease (acute or chronic) and etiological factor. By etiology are divided into the following types – bacterial, viral, chlamydial and fungal. The typical symptoms for bacte-rial conjunctivitis are copious discharge from the eyes; when dried, it gives a crust on the eyelashes and eyes. One of the problems arising from the use of various antimicrobial agents (biocides, antibiotics) is the ability of microorganisms consisting of representatives of one species or the association of microorganisms to form biofilms. Drugs that can prevent the development of biofilms or disrupt the structure are now of great interest all over the world. Recently, a number of guanidine-based polymeric preparations have become widely spread, the merits of which include a wide range of antimi-crobial activity, both with respect to bacteria, yeast, viruses, and with respect to vegetative cells and fungal spores. One of the promising oligomeric guanidine derivatives is a branched oligohexamethylene guanidine hydrosuccinate. In conclusion, we can say that cationic polymers have a number of advantages compared with the traditionally used antimicrobial substances. Proven high efficacy against a number of pathogenic microorganisms, especially against yeast fungi of the genus Candida and Pseudomonas aeru-ginosa, and low toxicity makes it possible to use oligohexamethienguanidine hydrosuccinate as substances of pharmaceutical use, including for creat-ing effective drugs for the treatment and prevention of infectious conjunctivitis.

eye diseases
infectious conjunctivitis
synthetic cationic polymers
oligohexamethyleneguanidine hydrosuccinate

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Zdravooxranenie: Federal`naya sluzhba gosudarstvennoj statistiki. [Oficz. sajt] URL: wcm/connect/rosstat_main/ros¬stat/ru/statistics/population/healthcare.
  2. Alfonso S.A., Fawley J.D., Lu X.A. Conjunctivitis // Primary Care: Clinics in Office Practice. 2015; 42(3):325–345.
  3. Chernakova G.M., Kleshheva E.A., Obrubov A.S., Ovsyanko A.A., Semenova T.B. Rol` laboratornoj diagnostiki pri sindrome krasnogo glaza // Al`manax klinicheskoj mediciny`. 2015. № 36. S. 59–66.
  4. Zhilyakova E.T., Zinchenko A.A., Novikov O.O., Popov N.N. Razrabotka metodiki opredeleniya miramistina i dimedrola v novy`x prolongirovanny`x glazny`x kaplyax dlya lecheniya bakterial`ny`x kon``yunktivitov // Nauchny`e vedomosti belgorodskogo gosudarstvennogo universiteta. Seriya: medicina. Farmaciya. 2015. T. 30. №10 (207). S. 211–217.
  5. Zhilyakova E.T., Baskadova A.V., Novikov O.O., Komissarov M.I., Fadeev A.N. Razrabotka metodiki rastvorimosti aciklovira // Nauchny`e vedomosti belgorodskogo gosudarstvennogo universiteta. Ser: medicina. Farmaciya. 2013. № 25(168). S. 38–41.
  6. Voskresenskaya L.K., Bezkorovajnaya I.N., Ryadnova O.Yu., Maksimuk O.Yu. E`ffektivnost` primeneniya protivovirusny`x preparatov v kompleksnoj terapii virusny`x kon``yunktivitov // Vіsnik problem bіologії і medicini. 2014. № 1(106). S. 76–79.
  7. Sakovich V.N. Adenovirusny`e porazheniya glaza: e`tiologiya, diagnostika, klinika, lechenie // Oftal`mologіya. 2015. № 2. S. 232–243.
  8. Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance // European Journal of Microbiology and Immunology. 2014; 4(1):26–33.
  9. Segal K.L., Lai E.C., Starr C.E. Management of acute conjunctivitis // Current Ophthalmology Reports. 2014; 2(3):116–123.
  10. Jhanji V., Chan T.C.Y., Li E.Y.M., Agarwal K., Vajpayee R. Adenoviral keratoconjunctivitis // Survey of Ophthalmology. 2015; 60(5):435–443.
  11. Chekina A.Yu., Marchenko L.N., Kuderko I.A., Vezhbiczkaya Yu.L., Akimova L.V., Ivankova L.A. Xlamidijny`e kon``yunktivity`: sovremennaya taktika lecheniya // Oftal`mologiya Vostochnaya Evropa. 2012. № 1. S. 32–39.
  12. Andalibi S., Haidaraet M., Bor N., Levin M. An update on neonatal and pediatric conjunctivitis // Current Ophthalmology Reports. 2015; 3(3):158–169.
  13. de Vries H.J.C. Skin as an indicator for sexually transmitted infections // Clinics in dermatology. 2014; 32(2):196–208.
  14. Taylor H.R., Burton M.J., Haddad D., West S., Wright H. Trachoma // The Lancet. 2014; 384(9960):2142–2152.
  15. Giske C.G. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin // Clinical Microbiology and Infection. 2015; 21(10):899–905.
  16. Golub A.V. Bakterial`ny`e bioplenki-novaya cel` terapii? // Klinicheskaya mikrobiologiya i antimikrobnaya ximioterapiya. 2012; 14(1):23–29.
  17. Gostev V.V., Sidorenko S.V. Bakterial`ny`e bioplenki i infekcii // Zhurnal infektologii. 2014. T. 2. №. 3. S. 4–15.
  18. Afinogenova A.G., Darovskaya E.N. Mikrobny`e bioplenki ran: sostoyanie voprosa // Travmatologiya i ortopediya Rossii. 2011. № 3.
  19. Jala J.F. Development of antimicrobial surfaces // The first European congresson microbial biofilms: Eurobiofilms. 2009; 2:51.
  20. Patent RU 2443684 S1, 2012¸ MPK C07C279/00, C08G73/00, A61L2/16. Razvetvlenny`e oligomery` na osnove proizvodnogo guanidina i soderzhashhee ix dezinficiruyushhee sredstvo / Kedik S.A., Sedishev I.P., Panov A.V., Zhavoronok E.S., Xa Kam An`.
  21. Afinogenov G.E., Panarin E.F. Antimikrobny`e polimery`. SPb: Gippokrat, 1993.
  22. Shatalov D.O., Kedik S.A., Zhavoronok E.S., Ajdakova A.V., Ivanov I.S., Evseeva A.S., Belyakov S.V., Biryulin S.I., Kovalenko A.V., Mixajlenko E.N. Opy`t i perspektivy` razvitiya ispol`zovaniya sinteticheskix antimikrobny`x veshhestv // Vse materialy`. E`nciklopedicheskij spravochnik. 2016. Vy`p. 8. S. 14–22.
  23. GOST R. 12.1. 007-76 Vredny`e veshhestva // Klassifikaciya i obshhie trebovaniya bezopasnosti. M.: Izdatel`stvo standartov. 1976.